Source: Annual Congress 2012 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Lares dos Santos, L. Fernandes, I. Sanches, F. Cruz e Costa, F. Barata (Coimbra, Portugal). Non-small cell lung cancer – Advanced disease: Barriers to inclusion in clinical trials and its impact on survival. Eur Respir J 2012; 40: Suppl. 56, 2928

Member's Comments

No comment yet.

Related content which might interest you: Survival outcomes in advance non-small cell lung cancer – A developing country scenario Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Octogenarians with non-small cell lung carcinoma – Advanced disease Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Lung function and quality of life after surgical treatment of non-small cell lung cancer – preliminary results Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014 Differences in epidemiological and clinical features in non-small cell lung cancer (NSCLC) in never and ever smokers Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Clinical trials in advanced stage lung cancer: A survey of patients‘ opinion about their treatment Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Non-small cell lung carcinoma–advanced disease (NSCLC-AD): Effectiveness of subsequent therapeutic lines and predictive factors of poor outcome Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 The effect of surgical specimen-derived phosphorus and lead concentrations in non-small cell lung cancer patients on disease course Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015 Non-small cell lung cancer: Are M1a and M1b the same stage? Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Enrolment in clinical trials enhances the survival benefit provided to lung cancer patients Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 EGF-receptor mutation in non-small cell lung cancer – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Neutrophil to lymphocyte ratio (NLR) as a predictor of poor prognosis in advanced non-small cell lung cancer Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016 Response to Immunotherapy in non-small cell lung cancer: the effect of weight Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Prognostic impact of secondary malignancies in non-small cell lung cancer (NSCLC) Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Symptom control in advanced non-small cell lung cancer (NSCLC): what is the influence of cisplatin-use, age, performance status and duration of chemotherapy? Analysis of a randomized database Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002